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Ginsenoside Rg1 and Rb1 are the major ingredients in two medicines called QiShengLi
(Z20027165) and QiShengJing (Z20027164) approved by China. These ingredients are
believed to mitigate forgetfulness. Numerous studies have confirmed that GRg1 and
GRb1 offer protection against Alzheimer’s disease (AD), and our morris water maze
(MWM) experiment also indicated that GRg1 and GRb1may attenuate memory deficits in
the 7-month-old SAMP8 mice; however, comprehensive understanding of their roles in
AD remains limited. This study systematically explored the mechanism at the genome
level of the anti-AD effects of GRg1 and GRb1 in a senescence-accelerated mouse
prone 8 (SAMP8) model through deep RNA sequencing. A total of 74,885 mRNA
transcripts were obtained. Expression analysis showed that 1,780 mRNA transcripts
were differentially expressed in SAMP8 mice compared with the SAMP8+GRg1 mice.
Moreover, 1,066 significantly dysregulated mRNA transcripts were identified between
SAMP8 and SAMP8+GRb1 mice. Analyses according to gene ontology and the
Kyoto Encyclopedia of Genes and Genomes revealed that oral administration of GRg1
and GRb1 improved the learning performance of the SAMP8 mouse model from
various aspects, such as nervous system development and mitogen-activated protein
kinase signaling pathway. The most probable AD-related transcriptional responses after
medication were predicted and discussed in detail. This study is the first to provide a
systematic dissection of mRNA profiling in SAMP8 mouse brain in response to GRg1
and GRb1 treatment. We explained their efficacy thoroughly from the source (gene-level
explanation). The findings serve as a theoretical basis for the exploration of GRg1 and
GRb1 as functional drugs with anti-AD activity.
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INTRODUCTION
Alzheimer’s disease (AD) is a progressive amnesic disorder characterized by age-dependent
memory loss and impairment of cognitive functions (Yaari and Corey, 2007; Roy et al., 2016).
According to reports, two types of AD exist. Sporadic AD accounts for 90–95% of all AD cases, and
the familial form of AD accounts for 5–10% (Bhat, 2010; Babusikova et al., 2011). Current statistics
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indicate that a person in America develops AD every 67 s. By
2050, a new case of AD is expected to develop every 33 s,
and nearly 1 million new cases per year is expected to arise
(Alzheimer’s Association, 2015). AD is becoming a major public
health problem, and discovering effective drugs for the treatment,
relief, or prevention of AD has become increasingly urgent.
Chinese medicinal herbs exert certain effects on the treatment
of neurodegenerative diseases (Howes et al., 2003). Panax
notoginseng, the root of Panax notoginseng (Burk.) F. H. Chen,
is a well-known traditional Chinese herbal medicine with a
long history of usage in East Asian countries (Yan et al.,
2014). Panax notoginseng contains more than 30 different
saponins called Panax notoginsenosidum (PNS). Ginsenosides
Rg1 (GRg1) and Rb1 (GRb1) are the major pharmacologically
active ingredients of Panax notoginseng (Du et al., 2003).
As eminent members of PNS, GRg1, and GRb1 are believed
to mediate the complex pathological mechanisms of AD.
Zhao et al. reported that GRg1 suppresses the signaling
transduction pathway of TLR3 and TLR4 and decreases
the inflammation factors induced by Aβ 25–35 in NG108-
15 cells (Zhao et al., 2014). Scientific evidence shows that
GRb1 reverses the changes in several direct or indirect
neuroinflammation markers of AD produced by ventricle
injection of Aβ 1–42 (Wang et al., 2011). Li et al. concluded that
GRg1 treatment affects all three metabolic pathways, and GRb1
treatment affects lecithin and amino acid but not sphingolipid
metabolism in AD mice (Li et al., 2015). These studies provided
several clues but not detailed insights and comprehensive
assessments.
In the present study, the mRNA profiles of the brain of
GRg1- and GRb1-treated senescence-accelerated mouse prone
8 (SAMP8) models at 7 months of age were explored through
RNA sequencing. The SAMP8 strain is a naturally derived model
that demonstrates cognitive, behavioral, and neuropathological
alterations similar to those observed in aged humans; it is a
FIGURE 1 | Structures of GRg1 and GRb1.
plausible model for exploring the complexity of AD (Butterfield
and Poon, 2005; Cheng et al., 2014; Kang et al., 2014). This
research systematically provided a molecular basis for the
therapeutic benefits of GRg1 and GRb1 in AD treatment. Thus,
GRg1 and GRb1may be potential therapeutic reagents for halting
or preventing AD progression.
MATERIALS AND METHODS
Preparation of GRg1 and GRb1
GRg1 (C42H72O14, molecular weight = 801.01, Figure 1) and
GRb1 (C54H92O23, molecular weight = 1,109.29, Figure 1) with
purity>98% were purchased from the Chinese National Institute
for the Control of Pharmaceutical and Biological Products
(Beijing, China). GRg1 and GRb1 were dissolved in sterile
distilled water before use.
Animals and Grouping
Three-month-old male SAMP8 mice (n = 45) were purchased
from Beijing WTLH Biotechnology Co., Ltd. Each mouse was
housed in a cage in standard specific pathogen-free conditions
(24 ± 2◦C, 45–55% humidity, and 12 h light/dark cycle). The
mice were allowed free access to water and food. The SAMP8
mice were randomly divided into three groups (n = 15 mice per
group), which received GRg1 (15 mg/kg/d), GRb1 (15 mg/kg/d),
and the vehicle (sterile distilled water) via oral gavage. After 4
months of GRg1 and GRb1 administration, three animals were
randomly selected from each group and anesthetized to collect
the cerebral cortex. The tissues were immediately frozen in liquid
nitrogen for RNA sequencing. Eight animals in each group were
also randomly selected for the morris water maze (MWM) test.
All of the animal procedures were approved by the
Institutional Animal Use and Care Committee of Beijing Normal
University and adhered to the “Guide for the care and use of
laboratory animals” (Clark et al., 1997).
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MWM Test
The spatial learning and memory of the mice were evaluated
through the MWM test (D’Hooge and De Deyn, 2001; Vorhees
and Williams, 2006). Briefly, in the hidden platform test (days
1–5), a platform was placed at the center of a suppositive
quadrant. The mice were subjected to two trials per day for
five consecutive days. During each trial, the mice were placed
in the maze at four different assigned points and allowed to
swim for 90 s. The escape latency was recorded by a software
upon mounting the platform. When a mouse failed to reach
the platform within 90 s, it was guided to the platform, and the
escape latency was recorded as 90 s. In both situations, the mice
were allowed to rest on the platform for 15 s and subsequently
placed in the home cage. The platform was removed in the spatial
probe test (day 6). The mice were released from the opposite
quadrant and allowed to swim freely for 60 s. All experiments
were conducted at approximately the same time daily.
RNA Extraction and Qualification
TRIzol reagent (Invitrogen, Carlsbad, CA, USA) was used to
isolate the total RNA of each sample. The purity of RNA
was checked with a NanoPhotometer R© spectrophotometer
(IMPLEN, Westlake Village, CA, USA). The concentration of
RNA was tested with Qubit R© RNA Assay Kit in Qubit 2.0
Flurometer (Life Technologies, CA, USA). In addition, RNA
integrity was assessed with RNA Nano 6000 Assay Kit in the
Bioanalyzer 2100 system (Agilent Technologies, Santa Clara, CA,
USA). The samples with RNA integrity number scores higher
than eight were used in this study.
Library Preparation and Sequencing
Nine cDNA libraries were constructed, i.e., three for the
SAMP8+GRg1 mice, three for the SAMP8+GRb1 mice, and
three for the SAMP8+vehicle mice. We utilized 3 µg of RNA
per sample as the input material for RNA sample preparation.
First, rRNA-depleted RNA was fragmented with NEBNext first
strand synthesis reaction buffer (5X). Second, a random hexamer
primer andM-MuLV reverse transcriptase (RNaseH−) were used
to synthesize the first-strand cDNA. Second-strand cDNA was
synthesized subsequently with DNA polymerase I and RNase
H. Third, the purified second-strand cDNA was ligated with
NEBNext adaptor after adenylation of the 3’ ends of the DNA
fragment, and 150–200 bp cDNA fragments were isolated. Then,
the cDNA libraries were enriched through PCR amplification
with Phusion high-fidelity DNA polymerase, universal PCR
primers, and index (X) primer. The Agilent bioanalyzer 2100
system was used to assess library quality. The libraries were
sequenced at the Novogene Bioinformatics Institute (Beijing,
China) on an Illumina HiSeq 4000 platform, and 150 bp paired-
end reads were generated after clustering of the index-coded
samples. Clustering was performed in a cBot cluster generation
system using the TruSeq PE Cluster Kit v3-cBot-HS (Illumina).
Transcriptome Assembly
Clean data were obtained after filtering out reads with adaptors
and poly-N > 10% and low-quality reads from raw data through
in-house perl scripts. The Q20, Q30, and GC contents of the clean
reads were calculated. All downstream analyses were based on the
good-quality clean reads. Paired-end clean reads were mapped to
the mouse genome sequence (ftp://ftp.ensembl.org/pub/release-
81/gtf/mus_musculus/) with TopHat v2.0.9 (Trapnell et al., 2009;
Kim et al., 2013). Cuﬄinks v2.1.1 was used to assemble the
mapped reads of each sample (Trapnell et al., 2010).
Expression Analysis
The protein-coding gene expression levels in each sample were
estimated according to fragments per kilo-base of exon per
million fragments mapped (FPKMs) and assessed with Cuﬄinks
v2.1.1 (Trapnell et al., 2010). Transcripts with a P < 0.05 were
considered differentially expressed.
Quantitative Polymerase Chain Reaction
(qPCR)
The results of RNA sequencing were validated through qPCR.
qPCR was performed with the LightCycler 480 real-time
PCR system and SYBR Green PCR Master Mix (TaKaRa
Biotechnology, Dalian, China). The specific quantitative primers
for 8 transcripts (four from SAMP8 vs. SAMP8+GRg1
and four from SAMP8 vs. SAMP8+GRb1) are listed in
Supplementary Table 1. The 20 µL reaction volume contained
0.5 µL of each primer, 8 µL of H2O, 1 µL of cDNA, and 10 µL
of 2× RealMasterMix (TaKaRa Biotechnology). The conditions
were 95◦C for 2 min followed by 40 cycles (95◦C for 20 s, 60◦C
for 30 s, and 68◦C for 30 s). Each experiment was performed in
triplicate.
Gene ontology (GO) and Kyoto
Encyclopedia of Genes and Genomes
(KEGG) Analyses
To understand the functional roles of the differentially expressed
protein-coding genes, we used the GOseq R package to conduct
an enrichment analysis (Young et al., 2010). GO terms with a P<
0.05 were considered significantly enriched. In addition, KEGG
enrichment analysis was performed with KOBAS software on the
differentially expressed protein-coding genes (Mao et al., 2005)
through a hypergeometric test. A hypergeometric P < 0.05 was
considered significant.
Statistical Analysis
Statistical analyses were performed with SPSS 20.0 software. All
data were expressed as the means ± standard error of the mean
(SEM). P < 0.05 were considered statistically significant. The
escape latency in the MWM test was compared through two-way
analysis of variance (ANOVA). One-way ANOVA was used to
analyze the rest index in the MWM test. Student’s t-test was used
to compare the qPCR results.
RESULTS
GRg1 and GRb1 Ameliorated Memory
Impairment in 7-Month-Old SAMP8 Mice
We performed the MWM test to evaluate the effect of GRg1 and
GRb1 on the cognitive function of the SAMP8 mouse model.
In the result, we introduced the MWM performance of the
senescence-accelerated mouse resistant 1 (SAMR1) mouse model
based on our previous study (Zhang et al., 2016). The SAMR1
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mouse model is widely used as a control strain (Ma et al., 2011).
As shown in Figure 2A, the mean escape latency of SAMP8 +
GRg1, SAMP8+GRb1, and SAMR1mice significantly decreased
compared with that of SAMP8 + vehicle mice (P < 0.05). In
the spatial probe test, the SAMP8 mice swam randomly in the
tank without knowing the target location, whereas the GRg1-
and GRb1-treated SAMP8 mice and SAMR1 mice searched
preferentially for the target quadrant and showed improved
memory (Figure 2B). In addition, the number of crossings and
the time spent in the target quadrant increased significantly in
the GRg1- and GRb1-treated SAMP8 mice and SAMR1 mice
compared with the SAMP8 mice (Figures 2C,D). No significant
difference was observed in the swimming speed of all the
groups (P > 0.05, Figure 2E), suggesting that the memory
impairments of SAMP8 mice were not caused by motor and
visual dysfunctions. Evidently, administration of GRg1 and GRb1
for 4 months significantly attenuated the memory deficit of
7-month-old SAMP8 mice.
Overview of RNA Sequencing
A total of 800,400,106 raw reads (251,783,324 for SAMP8,
277,307,450 for SAMP8+GRg1, and 271,309,332 for
SAMP8+GRb1) were generated. After discarding the reads with
adapters, poly-N > 10%, and any other possible contaminants,
784,513,910 clean reads (244,770,474 for SAMP8, 272,566,802
for SAMP8+GRg1, and 267,176,634 for SAMP8+ GRb1)
were obtained. The clean reads were mapped to the mouse
reference genome (ftp://ftp.Ensemble.org/pub/release-83/gtf/
mus_musculus/), and the mapping rates were approximately
70.72, 71.41, and 70.06% for the SAMP8, SAMP8+GRg1, and
SAMP8+GRb1 mice, respectively. The cuﬄinks results indicated
that 102,250 transcripts were assembled. A total of 74,885
protein-coding transcripts were identified. These mRNAs were
used for subsequent analysis.
Differential Expression Analysis: SAMP8
vs. SAMP8+GRg1 and SAMP8 vs.
SAMP8+GRb1
The mRNA expression levels and transcripts were estimated
with FPKMs. A total of 1,780 mRNA transcripts, including 768
upregulated and 1,012 downregulated transcripts (p < 0.05),
were differentially expressed in SAMP8+GRg1 mice relative
to SAMP8 mice (Supplementary Table 2). Meanwhile, 1,066
significantly dysregulated mRNA transcripts were identified
between SAMP8 and SAMP8+GRb1 mice (Supplementary
Table 3); 381 were upregulated in the SAMP8 mice, whereas 685
were downregulated in SAMP8+GRb1 mice (p < 0.05). Cluster
analysis of differentially expressed mRNAs was conducted with
heat maps (Figures 3A,B).
Quantitative Assessment
Eight differentially expressed mRNA transcripts (four from
SAMP8 vs. SAMP8+GRg1 and four from SAMP8 vs.
SAMP8+GRb1) were randomly selected to validate the accuracy
of RNA sequencing through qPCR. All the selected mRNA
transcripts were detected and exhibited significant differential
expressions (Figure 4). These results are consistent with RNA
sequencing data.
Functional Annotation
First, GO and KEGG analyses were performed on
1,780 significantly dysregulated mRNAs in SAMP8 vs.
SAMP8+GRg1. We derived 1,575 highly enriched GO terms
(Supplementary Table 4, P < 0.05) and 21 significantly enriched
FIGURE 2 | GRg1 and GRb1 administration ameliorated memory deficit in SAMP8 mice. Morris water maze tests were conducted on mice with or without
GRg1 and GRb1 (15 mg/kg/d, 4 months) treatment. Eight animals in each group. (A) Mean escape latency in the hidden platform test. (B) Swimming paths in the
spatial probe test. (C) Number of crossings in the spatial probe test. (D) Time spent in the target quadrant during the spatial probe test. (E) Average swimming speeds
of mice in the visible-platform test. *p < 0.05.
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FIGURE 3 | Cluster analysis by heat map. (A) Cluster analysis of
differentially expressed mRNAs in SAMP8 and SAMP8+GRg1 mice.
(B) Cluster analysis of differentially expressed mRNAs in SAMP8 and
SAMP8+GRb1 mice. The red markings indicate an increased expression, and
the blue markings indicate a decreased expression.
pathways (Supplementary Table 5, P < 0.05). We observed
several AD-associated pathways and terms, such as protein
processing in the endoplasmic reticulum, FoxO signaling, PI3K-
Akt signaling, and mitogen-activated protein kinase (MAPK)
signaling pathways, and several GO terms (e.g., GO: 0031175,
GO: 0007399, GO: 0045686, GO: 0010977, and GO: 0043409).
Overall, GRg1 affected AD from different angles.
GO and pathway enrichment analyses were also executed to
explore the functions of 1,066 significantly dysregulated mRNAs
in SAMP8 vs. SAMP8+GRb1. According to the GO survey,
1,368 GO terms were significantly enriched (Supplementary
Table 6, P < 0.05). Several terms, including GO: 0000188, GO:
0007420, and GO: 0007416, were closely related to AD. Eighteen
significantly enriched KEGG pathways (Supplementary Table 7,
P < 0.05) were detected. Several of these pathways, including
the MAPK signaling pathway, Notch signaling pathway, and
cholinergic synapse, were associated with AD. Overall, the
pathological process of AD may be regulated by GRb1 from
different aspects.
Comprehensive Analysis
In our previous study (Zhang et al., 2016), we identified 2,505
significantly dysregulated mRNA transcripts between SAMP8
and SAMR1 mice. Thus, to further understand the potential
protective effects of GRg1 and GRb1 on AD, we set two limiting
factors. One was that the gene should be significantly and
differentially expressed between SAMP8 vs. SAMP8+GRg1 or
SAMP8 vs. SAMP8+GRb1 mice. At the same time, the change
in the expression after administrating GRg1 or GRb1 must lean
toward the normal group (SAMR1). The other requirement was
that the selected gene should be associated with AD. According
to these requirements, the fulfilled genes were detected and
are listed in Tables 1, 2. For example, Mapk11 is an enzyme
encoded by the Mapk11 gene (Stein et al., 1997). This kinase
is closely related to p38 MAP kinase and is involved in the
development of AD. We found that the expression of Mapk11
in the SAMP8+GRb1 and SAMR1 mice was significantly lower
than that in the SAMP8 mice. In addition, an evident reduction
was observed in the SAMP8+GRg1 mice, but this reduction was
not significant. In short, we predict that GRg1 and GRb1 may
regulate the expression of the abovementioned genes and are
possibly involved in the adjustment of AD.
DISCUSSION
The first detailed record of the medicinal use of Panax
notoginseng was indicated in the Compendium of Materia
Medica, which was written by Li Shizhen and published in A.D.
1596 (Chinese Ming Dynasty) (Zhang and Fang, 2004). PNS, the
active ingredient extracted from the root of Panax notoginseng
(Burk.) F.H. Chen (Araliaceae), has been extensively used to treat
various diseases. Li et al. reported that PNS injections are widely
applied in clinical situations in China (Li et al., 2009). GRg1
and GRb1, as known members of PNS, attract great attention,
especially in reducing the risk of neurodegenerative diseases,
such as AD (Wang et al., 2011; Kim et al., 2014; Zhao et al.,
2014; Li et al., 2015). However, we believe that staying at this
level is far from enough. RNA sequencing (Ozsolak and Milos,
2011), a modern technology, allows for the investigation of the
AD-resistant effects of GRg1 and GRb1 in unprecedented detail.
In this study, the 7-month-old SAMP8 mice developed severe
deficits in learning and memory, and the MWM experiment
confirmed this result. SAMP8 mice at this age are relatively
“old” in their average life span of 12 months. Meanwhile, the
SAMP8 strain is a naturally derived model and shares cognitive,
behavioral, and neuropathological alterations observed in aged
humans; it can be considered an appropriate animal model
to understand the pathogenic mechanisms of AD, especially
sporadic AD (Cheng et al., 2014; Kang et al., 2014). However,
the transgenic mouse models of AD, such as 3xTg-AD, may
simply represent the uncommon familial AD. The primary goal
of this research was to systematically analyze the mRNA profiles
of the brain of SAMP8 mice after 4 months of GRg1 and GRb1
administration through RNA sequencing. The results indicate
that GRg1 and GRb1 can help restrict the development and
progression of AD.
First, we identified a total of 74,885 mRNAs in SAMP8,
SAMP8+GRg1, and SAMP8+GRb1 mice brains by using the
Illumina HiSeq 4000 platform. Then, we compared the mRNA
expressions of the SAMP8 and SAMP8+GRg1 mice. We also
measured the differential mRNA expression between SAMP8
and SAMP8+GRb1 mice. A total of 1,780 dysregulated mRNA
transcripts transcripted from 1,714 genes were detected in the
SAMP8 vs. SAMP8+GRg1 group. Moreover, 1,066 differentially
expressed mRNA transcripts corresponded to the 1,025 genes
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FIGURE 4 | Validation of transcript expression by qPCR. Data are presented as the mean ± SE (n = 3). β-actin gene was used as a housekeeping internal
control. Transcript expression was quantified relative to the expression level of β-actin using the comparative cycle threshold (1CT) method. *p < 0.05.
TABLE 1 | AD-related genes identified after treatment with GRg1.
Gene Transcript ID SAMP8
FPKM
SAMP8+Rg1
FPKM
SAMR1
FPKM
Bche ENSMUST00000029367 0.98 1.33 1.30
Fgfr1 ENSMUST00000084027 1.37 2.21 2.23
Dusp1 ENSMUST00000025025 9.07 10.89 16.53
Cdkn2b ENSMUST00000097981 0.29 0.52 0.62
Flna ENSMUST00000114299 3.23 4.64 4.87
Glp1r ENSMUST00000114574 0.27 0.48 0.77
Slc39a7 ENSMUST00000169397 5.97 1.98 2.59
Calr ENSMUST00000003912 196.95 159.62 163.60
Mapk11 ENSMUST00000088823 14.36 12.77 11.81
Trpc6 ENSMUST00000050433 22.02 18.76 4.37
Smad3 ENSMUST00000034973 20.09 16.76 16.99
Pdia6 ENSMUST00000057288 85.99 61.29 68.01
Pdia4 ENSMUST00000077290 36.14 24.39 29.83
Xbp1 ENSMUST00000063084 55.75 39.55 42.90
Arntl ENSMUST00000047321 17.87 13.26 13.49
Gm10053 ENSMUST00000073080 1.79 1.06 0.42
Pfkfb3 ENSMUST00000028114 5.22 3.46 4.07
Htr5b ENSMUST00000055884 0.85 0.47 0.48
FPKM, fragments per kilobase of exon per million fragments mapped. FPKM was used to
determine the differential expression of the transcripts.
found in the SAMP8 vs. SAMP8+GRb1 group. Subsequently,
qPCR was used to measure the accuracy of RNA sequencing.
Eight dysregulated mRNAs were randomly selected for the test.
All results were consistent with the RNA-seq data. The qPCR
results confirmed that our resultant mRNAs were of high quality.
Evidently, this research provides a solid foundation for further
exploration.
GO and KEGG pathway analyses were also performed on
the coding genes associated with the significant mRNAs to
study the possible biological, cellular, and molecular functions of
TABLE 2 | AD-related genes identified after treatment with GRb1.
Gene Transcript ID SAMP8
FPKM
SAMP8+Rb1
FPKM
SAMR1
FPKM
Bche ENSMUST00000029367 0.98 1.27 1.30
Kat2a ENSMUST00000103118 1.24 2.24 2.50
Dusp1 ENSMUST00000025025 9.07 16.56 16.53
Cdkn2b ENSMUST00000097981 0.29 0.54 0.62
Fos ENSMUST00000021674 11.40 20.61 17.49
Glp1r ENSMUST00000114574 0.27 0.48 0.77
Nr4a1 ENSMUST00000023779 17.55 27.11 25.48
Calr ENSMUST00000003912 196.95 171.07 163.60
Mapk11 ENSMUST00000088823 14.36 11.96 11.81
Mme ENSMUST00000029400 0.80 1.48 1.62
Smad3 ENSMUST00000034973 20.09 16.09 16.99
Pdia6 ENSMUST00000057288 85.99 67.21 68.01
Pdia4 ENSMUST00000077290 36.14 26.71 29.83
Xbp1 ENSMUST00000063084 55.75 43.00 42.90
Syk ENSMUST00000055087 0.73 0.33 0.53
Htr3a ENSMUST00000003826 4.05 3.33 3.20
Pfkfb3 ENSMUST00000028114 5.22 3.19 4.07
Htr5b ENSMUST00000055884 0.85 0.46 0.48
FPKM, fragments per kilobase of exon per million fragments mapped. FPKM was used to
determine the differential expression of the transcripts.
these mRNAs in AD progression. AD is a multifactorial disease,
and many theories have been advanced concerning its causes,
including neuron loss, Aβ deposition, tau neuropathology,
immune system dysfunction, synapse injury, oxidative stress,
and mitochondrial dysfunction (Armstrong, 2013). As expected,
our analysis showed that GRg1 and GRb1 exert multi-level
anti-AD effects; for example, the MAPK signaling pathway,
Notch signaling pathway, PI3K-Akt signaling pathway, and GO
terms (e.g., GO: 0000188, GO: 0007420, and GO: 0031175) were
affected.
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To conceptualize these findings, we established reasonable
limitations and further refined the closest results. After treatment
with GRg1, we identified 6 upregulated genes, namely, Bche,
Fgfr1, Dusp1, Cdkn2b, Flna, and Glp1r, and 12 downregulated
genes, namely, Slc39a7, Calr, Mapk11, Trpc6, Smad3, Pdia6,
Pdia4, Xbp1, Arntl, Gm10053, Pfkfb3, and Htr5b. Meanwhile,
in the GRb1 experimental group, 8 genes (Bche, Kat2a, Dusp1,
Cdkn2b, Fos, Nr4a1, Mme, and Glp1r) were up-regulated, and
10 genes (Calr, Mapk11, Smad3, Pdia6, Pdia4, Xbp1, Pfkfb3, Syk,
Htr3a, and Htr5b) were downregulated. Interestingly, 12 genes,
including 4 upregulated genes (Bche, Dusp1, Cdkn2b, and Glp1r)
and 8 downregulated genes (Calr,Mapk11, Smad3, Pdia6, Pdia4,
Xbp1, Pfkfb3, and Htr5b) were affected by both GRg1 and GRb1.
All of the abovementioned genes showed an expression similar
to that in the normal mice (SAMR1). In addition, these genes are
highly relevant to AD. Earlier in the article, we discussedMapk11
(Stein et al., 1997). Neprilysin, which is encoded by Mme, is one
of the most important Aβ-degrading enzymes in the prevention
of AD pathology (Miners et al., 2012). Trpc6, a transient receptor
potential canonical (TRPC) related gene, has been reported as
the molecular entity associated with Ca2+ entry activity (Zhu
et al., 1996) and may participate in the AD process. Brain
development is impaired in fos –/– mice (Velazquez et al., 2015).
As observed, GRg1 and GRb1 are effective Chinese medicines
that can be used to prevent and treat AD with multi-system,
multi-target, and multi-directional comprehensive regulation.
However, assessment of the curative effects of GRg1 and GRb1
merits further investigation in large-scale, clinical studies. This
endeavor is going to be an enormous challenge in the future.
In conclusion, we investigated SAMP8 mice brain mRNAs
after 4 months of GRg1 and GRb1 administration. Evidently,
intake of GRg1 and GRb1 restored the cognitive function of
SAMP8 mouse and exerted robust neuroprotective effects in
different ways. This strategy provides an invaluable resource for
the clinical application of GRg1 and GRb1 in treating AD.
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